It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL …
COVID-19 has turned the world upside down, but the market’s most recent surge has Wall Street observers wondering if the situation is on the mend. Rallying on April 17 thanks to encouraging data from Gilead’s remdesivir COVID-19 drug …
A stock can experience a pullback for a variety of reasons, be it disappointing quarterly results, the impact of internal politics, or the …
Healthcare stocks have a reputation of keeping investors on their toes. The possibility of surging price action, or conversely, earth shattering drops is …
Are you prone to sudden surges of joy, abruptly followed by sinking bouts of misery? Do you react disproportionately to good or bad …
Heron Therapeutics, Inc. (NASDAQ:HRTX) announced positive topline results from its Phase 2 study of the investigational agent HTX-011 in subjects undergoing abdominoplasty (Study …
Heron Therapeutics Inc (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, …
In a research report published Wednesday, Cantor analyst Chiara Russo reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX) with a price …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …
Heron Therapeutics Inc (NASDAQ:HRTX) announced that the U.S.
